Point72 Asset Management
DNLI icon

Point72 Asset Management’s Denali Therapeutics DNLI Stock Holding History

Point72 Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$434K Buy
+22,600
New +$450K ﹤0.01% 3180

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management's DNLI Position: Q1 2026 in Review

Point72 Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 1,700,000 shares — an estimated $33.8M sold.

Point72 Asset Management first reported a position in DNLI in Q3 2022 and held it in 10 quarters. The position peaked at $36.6M in Q3 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Point72 Asset Management reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,700,000 Denali Therapeutics shares in Q1 2026, an estimated $33.8M.
  • Point72 Asset Management first reported a position in Denali Therapeutics in Q3 2022 and held it in 10 quarters.
  • Point72 Asset Management's Denali Therapeutics position peaked at $36.6M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.